About the Symposium and Dr. Comis

The ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) hosts the Robert L. Comis, MD Translational Science Symposium at Group meetings. This plenary symposium is open to all attendees. The overall goal of the event is to seed ideas for ECOG-ACRIN’s various scientific committees to explore within and across its scientific programs. Each symposium offers a focused examination of a particular field of scientific opportunity.

Robert L. Comis, MD was an innovative researcher who recognized the potential for translational research to advance cancer prevention, detection, and treatment. Some of the most important national late-stage clinical trials were conducted under his leadership of the Group (1995-2017). He spearheaded scores of scientific discoveries that changed clinical practice across multiple types of cancer. ECOG-ACRIN is pleased to honor him through this event.

Dr. Comis’ interest in oncology began early in his career at the National Cancer Institute (NCI) when he was sent to Uganda to provide chemotherapy to children suffering from Burkitt’s lymphoma. After a fellowship at the Dana-Farber Cancer Institute, he embarked on a career focused on lung cancer and developmental therapeutics. He built centers of excellence in the research and treatment of cancer, first in Syracuse then at Fox Chase Cancer Center and Thomas Jefferson University in Philadelphia.

Dr. Comis envisioned the merger that resulted in the ECOG-ACRIN Cancer Research Group in 2012. He led the effort to coalesce the new group into what it is today: a scientific community of researchers in cancer biology, immunology, therapeutics, molecular and imaging diagnostics, and comparative effectiveness and patient-reported outcomes research, as well as bioinformatics and biostatistical expertise.

A giant in the field, he was a tireless advocate for patient access to trials and a champion for underserved populations. As a mentor, he helped launch many careers by fostering scientific inquiry among early-career oncologists. Many of his trainees are the new leaders in the field, and will carry on his legacy.
## Agenda

### Value Proposition

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Presenter(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>3:30 PM</td>
<td>Welcome and Summary of Symposium</td>
<td>Peter J. O’Dwyer, MD and Mitchell D. Schnall, MD, PhD ECOG-ACRIN and University of Pennsylvania</td>
</tr>
<tr>
<td>3:35 PM</td>
<td>The Value of RWD and Practical Implementation Video</td>
<td>Donna R. Rivera, PharmD, MS US Food and Drug Administration</td>
</tr>
<tr>
<td>3:40 PM</td>
<td>Pharmaceutical Company Perspective on RWD</td>
<td>Martina von Meyenn, PhD Roche</td>
</tr>
<tr>
<td>3:55 PM</td>
<td>Data Sources and Applications for Real-World Evidence in Oncology</td>
<td>Ronac Mamtani, MD, MSCE University of Pennsylvania</td>
</tr>
</tbody>
</table>

### Roadmap for Implementation

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Presenter(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>4:10 PM</td>
<td>Looking Beyond Clinical Trials to Inform Their Design and Interpretation</td>
<td>David E. Gerber, MD UT Southwestern Medical Center</td>
</tr>
<tr>
<td>4:25 PM</td>
<td>Real World Data; Reaching Inaccessible Populations, Casting a Broad Net</td>
<td>Otis W. Brawley, MD Johns Hopkins University</td>
</tr>
<tr>
<td>4:40 PM</td>
<td>Innovating Evidence Generation - An Industry Perspective</td>
<td>Marlene Thomas, PhD Roche</td>
</tr>
<tr>
<td>4:55 PM</td>
<td>Considerations for Use of Real World Data in External Controls and Novel Trial Designs</td>
<td>Meghna Samant, PhD Flatiron Health</td>
</tr>
<tr>
<td>5:10 PM</td>
<td>Panel Discussion</td>
<td>Peter J. O’Dwyer, MD and Mitchell D. Schnall, MD, PhD ECOG-ACRIN and University of Pennsylvania</td>
</tr>
<tr>
<td>5:25 PM</td>
<td>Closing Remarks</td>
<td>Mitchell D. Schnall, MD, PhD ECOG-ACRIN and University of Pennsylvania</td>
</tr>
</tbody>
</table>

## Speakers

### Martina von Meyenn, PhD

*Roche*

Dr. von Meyenn leads the Global Medical Real World Data (RWD) Chapter at F. Hoffmann La-Roche. In her role she focuses on providing strategic guidance in the organization on the most meaningful use of RWD for clinicians and patients at the point of care, with a long term view to be future proof in an evolving healthcare ecosystem. Dr. von Meyenn is passionate about realizing the value that RWD can bring to healthcare systems and frequently engages in policy discussions and other multi-stakeholder consortia in an effort to share learnings from innovative RWD solutions and help the ideation process around ways to overcome current challenges.
Speakers

Mitchell D. Schnall, MD, PhD  
*University of Pennsylvania*

Dr. Schnall is the co-chair of the ECOG-ACRIN Cancer Research Group, a position he has held since the founding of the Group in 2012. Dr. Schnall co-leads the organization’s governance and is a member of several scientific committees. He currently oversees the Tomosynthesis Mammographic Imaging Screening Trial (TMIST) and has a significant influence on emerging imaging technologies, including those in optical imaging. He is chairman of the Department of Radiology and the Eugene P. Pendergrass Professor of Radiology at the Perelman School of Medicine, University of Pennsylvania in Philadelphia. He is a physician at Penn Medicine within its Abdominal Imaging Services program. Dr. Schnall is an international leader in translational biomedical and imaging research, working throughout his career across the interface between basic imaging science and clinical medicine to ensure effective integration of radiology research with other medical disciplines.

Marlene Thomas, PhD  
*Roche*

Dr. Thomas is the Global Medical Lead for Integrated Healthcare Solutions at Roche. Her background is in biochemistry and cancer biology and she now works at the interface of health-tech and bio-tech, combining advanced technologies with high quality therapies to support personalized healthcare concepts. Driven by her passion for healthcare innovations, she’s engaged for a more integrated way to deliver healthcare.

Otis W. Brawley, MD  
*Johns Hopkins University and the Sidney Kimmel Comprehensive Cancer Center*

Dr. Brawley is the Bloomberg Distinguished Professor of Oncology and Epidemiology at Johns Hopkins University. He is an authority on cancer screening and prevention and leads a broad interdisciplinary research effort focused on cancer health disparities. Prior to coming to Hopkins, he served as the chief medical and scientific officer of the American Cancer Society for more than a decade. Brawley is a Fellow of the Royal College of Physicians (London), a Fellow of the American Society of Clinical Oncology, a Fellow of the American Association for Cancer Research Academy, a Fellow of the American College of Epidemiology and one of the few physicians to be named a Master of the American College of Physicians. He is an elected member of the National Academy of Medicine.

David E. Gerber, MD  
*UT Southwestern Medical Center*

Dr. Gerber is a professor of internal medicine and population and data sciences at UT Southwestern Medical Center. Within the Harold C. Simmons Comprehensive Cancer Center, he serves as associate director for clinical research and as co-leader of the Experimental Therapeutics Program. Dr. Gerber is board certified in internal medicine and medical oncology. He is highly active in his research pertaining to lung cancer, including clinical trials. Dr. Gerber serves on several committees at UT Southwestern and is an active participant for the Lung Cancer Education Committee of the American Society of Clinical Oncology (ASCO) and the Career Development Committee with the International Association for the Study of Lung Cancer. He has served on the editorial board of the *Journal of Clinical Oncology* and on grant review committees for ASCO and the Department of Defense.
Speakers

Ronac Mamtani, MD, MSCE  
*University of Pennsylvania*

Dr. Mamtani is a genitourinary medical oncologist and cancer outcomes researcher. The principal goal of his research program is to improve the safety and effectiveness of urologic cancer care using observational epidemiology. Dr. Mamtani has been a standing member of the Scientific Program Committee in Health Services Research for the American Society of Clinical Oncology, the Scientific Advisory Board for the Bladder Cancer Advocacy Network, and National Comprehensive Cancer Network Clinical Practice Guidelines Committee for Bladder Cancer.

Peter J. O’Dwyer, MD  
*University of Pennsylvania and the Abramson Cancer Center*

Dr. O’Dwyer is the co-chair of the ECOG-ACRIN Cancer Research Group since May 2017. A medical oncologist with expertise in gastrointestinal and pancreatic cancers, Dr. O’Dwyer is a physician at Penn Medicine and a professor of medicine at the University of Pennsylvania since 1999. Within ECOG-ACRIN, he co-chairs the landmark NCI-MATCH precision medicine cancer trial. He is the CEO and chair of the PrECOG, LLC Board of Managers and president of the ECOG Research and Education Foundation. Dr. O’Dwyer received his medical degree at the University of Dublin, Trinity College, and completed his residency at the Hammersmith Hospital in London. After a fellowship at the Baltimore Cancer Research Center, he became a senior investigator in the Division of Cancer Treatment at the National Cancer Institute. Dr. O’Dwyer previously led the Developmental Therapeutics Programs at Fox Chase Cancer Center and the University of Pennsylvania.

Donna R. Rivera, PharmD, MS  
*US Food and Drug Administration*

Dr. Rivera is the Associate Director for Pharmacoepidemiology in the Oncology Center of Excellence (OCE) at the FDA. She leads the Oncology Real World Evidence (RWE) Program, focused on the use of Real World Data (RWD) and RWE for regulatory purposes, and management of the RWD research portfolio strategy and development of regulatory policy to support the OCE mission. Dr. Rivera has interests in the use of RWD to advance health equity, observational study designs and methodological approaches, and appropriate uses of RWD for drug development to increase access of effective therapies to patients. She is a Scientific Executive Committee member for the COVID-19 and Cancer Consortium and leads Project Post COVIDity, a collaborative RWD effort to assess longitudinal sequelae, outcomes, safety, vaccination, and immunity.

Meghna Samant, PhD  
*Flatiron Health*

Dr. Samant is the Vice President of Quantitative Sciences at Flatiron Health, a health technology company that aggregates, processes, and analyzes electronic health record data from cancer patients in the US. In her role, she oversees a group of biostatisticians, epidemiologists, and health outcomes researchers working on real world observational studies and research on a variety of topics including real-world endpoints, claims, real-world imaging, and clinico-genomics database. Prior to joining Flatiron, Dr. Samant worked extensively in clinical trials at Roche/Genentech spanning early, late, and post-marketing phases of drug development across solid tumors and hematology. She also held broader leadership positions including clinical development team leader for Kadcyla and led a team focused on decision-making for the hematology portfolio. Dr. Samant is a biostatistician by training and received her PhD in Biostatistics from UCLA.